Biopharmaceutical company Lipum is developing a new biological drug for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases. The next major goal is to initiate a first clinical study with the candidate SOL-116. CEO Einar Pontén attended the BioStock Investor Meeting in Stockholm and told us more about the way forward.
See Lipum’s presentation below.
Please note that the presentation was recorded before yesterday’s news that Lipum’s board of directors has resolved on a directed issue of approximately 39 MSEK.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.